SETD2 and breast carcinoma: Prior analyses demonstrate that a combination of baseline prognostic features (including clinical stage) along with a gene expression index related to hormonal-related transcription (the SET2,3 assay) is significantly associated with outcomes for HR+HER2- breast cancer treated with NAC17.